Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising outcomes in initial clinical assessments . Ongoing https://ez-bookmarking.com/story21315444/retatrutide-emerging-studies-and-possible-clinical-uses